Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Abbott Laboratories vs. DexCom

By Keith Speights - Jun 2, 2019 at 12:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Which stock wins in a one-on-one matchup between these two leaders in continuous glucose monitoring systems?

Abbott Laboratories (ABT -1.57%) and DexCom (DXCM -7.13%) turned in stellar performances in 2018. Abbott's shares jumped 27%, while DexCom stock more than doubled. It's a different story so far this year, though. Both medical device stocks lag well behind the S&P 500.

Investors shouldn't give up on either of these stocks because they've underperformed over a short period. Both Abbott and DexCom should have solid long-term growth prospects. But which stock is the better pick right now? Here's how Abbott and DexCom compare in three key areas.

Woman holding palms upward with a chalkboard drawing of scales behind her

Image source: Getty Images.

Growth prospects

DexCom is the hands-down winner when it comes to recent growth rates. The company's revenue soared 52% year over year to $280.5 million in the first quarter of 2019. That makes Abbott's Q1 revenue growth of 2% look puny by comparison.  

Wall Street definitely views DexCom as having better growth prospects. Analysts project average annual earnings growth of 140% over the next five years compared to growth of close to 12% for Abbott during the same period. 

It's important to note, though, that Abbott's product lineup is much more diversified than DexCom's. Abbott claims four multibillion-dollar business segments: diagnostics, established pharmaceuticals, medical devices, and nutrition. Each of these segments markets a wide lineup of products. DexCom makes nearly all of its money from its G6 continuous glucose monitoring (CGM) system. 

DexCom's reliance on the G6 system arguably makes its growth prospects riskier than Abbott's. Spruce Point Capital Management analyst Ben Axler thinks that DexCom's growth could be in trouble when Abbott launches its second-generation Freestyle Libre CGM system. Although the G6 system will still offer more features than the new Freestyle Libre, Abbott is expected to price its system around 80% below the G6 price. 

On the other hand, Freestyle Libre should continue to fuel growth for Abbott. The big healthcare company should also benefit from several other new products, including its HeartMate 3 left ventricular assist device. It should also see higher sales from MitraClip's new indication in treating secondary mitral regurgitation, a leaky heart valve resulting from advanced heart failure.

Dividends

There's no contest as to which stock has the better dividend, because DexCom doesn't pay a dividend while Abbott does.

Abbott's dividend yield currently stands at a respectable 1.61%. What's more impressive is the company's commitment to its dividend program. Abbott recently declared its 381st consecutive quarterly dividend. The company is a member of the elite group known as Dividend Aristocrats and has increased its dividend payout for 47 years in a row.

Valuation

Neither of these stocks looks cheap right now. Abbott Labs' shares trade at 21 times expected earnings. But DexCom's forward earnings multiple of 101 would probably be viewed by most investors as astronomical.

However, we do need to factor growth prospects into the valuations of these stocks. Remember that Wall Street has much loftier expectations for DexCom's growth than it does for Abbott. As a result, DexCom's price-to-earnings-to-growth (PEG) ratio of 1.1 makes its stock appear to be more attractively valued than Abbott, which has a PEG ratio nearly twice as high. 

Better buy

I like both of these stocks. Which is the better pick? I hate to equivocate, but that's what I'm going to do.

Abbott Labs is by far the better choice for conservative investors. The company is about as steady as they come. It pays a great dividend. And Abbott has solid long-term growth prospects. 

If you're looking for more aggressive growth, though, DexCom will probably be a better fit. Although it's possible that Abbott's new Freestyle Libre CGM could hamper growth for DexCom's G6, I think the market is big enough for both products. I'm also bullish about DexCom's long-term prospects with its more advanced (and less expensive) G7 system likely on the way by late next year.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$112.74 (-1.57%) $-1.80
DexCom, Inc. Stock Quote
DexCom, Inc.
DXCM
$308.49 (-7.13%) $-23.67

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
328%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.